title: Cutaneous Reactions in Children Treated with the Mitogen-Activated Protein Kinase Extracellular Signal-Regulated Kinase Inhibitor Trametinib for Neural Tumors.
abstract: BACKGROUND
  The mitogen-activated protein kinase (MAPK) pathway is a target for the treatment of a growing number of malignancies. The cutaneous reactions to medications that inhibit this pathway have not been described in children.
  
  
  METHODS
  A retrospective chart review was completed for eight children with neural tumors treated with the MAPK extracellular signal-regulated kinase inhibitor trametinib. All children were evaluated by a pediatric dermatologist with documentation of cutaneous findings.
  
  
  RESULTS
  All patients had at least two separate skin reactions while on treatment with trametinib. Common skin findings included xerotic dermatitis, bacterial folliculitis, acneiform eruptions, paronychia, and hair thinning. No child needed to discontinue use of trametinib due to cutaneous toxicities.
  
  
  CONCLUSIONS
  Cutaneous reactions are common in children receiving trametinib. Identification of these reactions is the initial step in establishing treatment guidelines that will minimize skin eruptions and subsequent interruption of trametinib treatment.
authors.affiliation: Division of Pediatric Dermatology, Department of Dermatology, University of Minnesota, Minneapolis, Minnesota.
authors.forename: Christina
authors.initials: C
authors.lastname: Boull
authors.affiliation: Division of Pediatric Dermatology, Department of Dermatology, University of Minnesota, Minneapolis, Minnesota.
authors.forename: Kristen
authors.initials: K
authors.lastname: Hook
authors.affiliation: Department of Pediatric Hematology/Oncology, University of Minnesota, Minneapolis, Minnesota.
authors.forename: Christopher
authors.initials: C
authors.lastname: Moertel
authors.affiliation: Division of Pediatric Dermatology, Department of Dermatology, University of Minnesota, Minneapolis, Minnesota.
authors.forename: Sheilagh
authors.initials: S
authors.lastname: Maguiness
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005076:Exanthema / Q000139:chemically induced*; D048049:Extracellular Signal-Regulated MAP Kinases / Q000037:antagonists & inhibitors; D005260:Female; D006801:Humans; D008297:Male; D018302:Neoplasms, Neuroepithelial / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011728:Pyridones / Q000009:adverse effects* / Q000627:therapeutic use; D011744:Pyrimidinones / Q000009:adverse effects* / Q000627:therapeutic use; D012189:Retrospective Studies
chemical_list: D047428:Protein Kinase Inhibitors; D011728:Pyridones; D011744:Pyrimidinones; C560077:trametinib; D048049:Extracellular Signal-Regulated MAP Kinases